WHO Protocol for Impact Assessment of Hepatitis B Immunization

Dr. Steven Wiersma
WHO Geneva
Kyiv, Ukraine
May 27, 2004
Documents in Production
Field Test Versions

- Assessing the impact of hepatitis B immunization programmes--Strategies, overview of issues and recommendations
- The hepatitis B vaccine coverage and HBV infection marker survey
Why Impact Assessment?

- Basic tenet of disease control...cannot effectively prevent disease without surveillance for that disease
- Coverage is a process indicator
- Impact measures outcome of interest—for hepatitis B—chronic infection, chronic disease or death
Why Serological Surveillance?

• Acute disease surveillance not present or not adequate
• Cancer registries not present or not adequate
• Death data not present or not adequate
When?

- Simple tools needed for use at country level when acute/chronic hepatitis surveillance, cancer registry, death data not present/adequate
- Helpful when decision makers want more information
- Helpful when programmatic problems suspected (e.g. freezing, coverage)
- Probably not needed by all countries (regional info available)
Next Steps

• Pilot tests in 3 countries during 2004 (Oman, Mongolia, TBD)
• Refinements, inputs from users, and further testing in 2005
Specific Issues

- Lab algorithm
  - Anti-HBc $\rightarrow$ HBsAg
- Lab QC/QA
  - Country example
- Methods: cluster survey in school age children vs convenience samples vs others
Still Needed

- Input from partners and interested parties
- Pilot test results from countries
- More data
Questions?